Non-Small Cell Lung Cancer

About
Mappings

OncoTree: Non-Small Cell Lung Cancer (oncotree:NSCLC)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Adagrasib
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib
EMA (3) FDA (2) v::ALK Non-Small Cell Lung Cancer Alectinib
EMA (1) FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
EMA (1) FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
EMA (1) FDA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
EMA (2) FDA (1) v::ALK Non-Small Cell Lung Cancer Brigatinib
EMA (1) FDA (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib
EMA (1) FDA (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib
FDA (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
EMA (2) FDA (1) v::ALK Non-Small Cell Lung Cancer Ceritinib
EMA (2) FDA (1) v::ALK Non-Small Cell Lung Cancer Crizotinib
EMA (1) FDA (1) v::ROS1 Non-Small Cell Lung Cancer Crizotinib
EMA (2) FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
EMA (1) FDA (1) v::ROS1 Non-Small Cell Lung Cancer Entrectinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
EMA (2) FDA (1) v::ALK Non-Small Cell Lung Cancer Lorlatinib
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Mobocertinib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
EMA (2) FDA (3) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
EMA (2) FDA (3) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
EMA (1) FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) v::RET Non-Small Cell Lung Cancer Pralsetinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
EMA (1) FDA (1) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib
EMA (1) FDA (1) v::RET Non-Small Cell Lung Cancer Selpercatinib
EMA (1) FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib
EMA (1) FDA (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib
EMA (1) FDA (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib
EMA (1) FDA (1) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (3) FDA (2) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib
EMA (3) FDA (2) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
EMA (1) FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
FDA (1) v::NRG1 Non-Small Cell Lung Cancer Zenocutuzumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Ensartinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
EMA (1) ERBB2 amplification Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Afatinib
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab
EMA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) CD274 amplification, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab
EMA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
EMA (2) BRAF p.V600K Non-Small Cell Lung Cancer Dabrafenib, Trametinib
EMA (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (2) EGFR oncogenic variants Non-Small Cell Lung Cancer Erlotinib
EMA (2) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Dacomitinib
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pemetrexed, Tislelizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pemetrexed, Tislelizumab
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) v::ROS1 Non-Small Cell Lung Cancer Taletrectinib
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Sunvozertinib
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Docetaxel, Nivolumab